Intravesical and systemic chemotherapy in the management of superficial bladder cancer.
Before deciding to begin intravesical prophylaxis, the physician must categorize the patient with respect to the stage of the tumor and the multiplicity of lesions. This may require mucosal biopsies in order to determine whether the patient had unifocal or multifocal disease. Thiotepa, mitomycin C, and doxorubicin hydrochloride are discussed specifically and compared.
D000287:Administration, Topical; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001706:Biopsy; D002295:Carcinoma, Transitional Cell / Q000175:diagnosis; D002945:Cisplatin / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage; D004724:Endoscopy; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local; D011897:Random Allocation; D012306:Risk; D013852:Thiotepa / Q000008:administration & dosage; D001743:Urinary Bladder / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*; D014815:Vitamins / Q000627:therapeutic use
D000970:Antineoplastic Agents; D008937:Mitomycins; D014815:Vitamins; D016685:Mitomycin; D004317:Doxorubicin; D003520:Cyclophosphamide; D013852:Thiotepa; D002945:Cisplatin; D008727:Methotrexate